Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQWL | ISIN: US60458C1045 | Ticker-Symbol: K6S
Tradegate
27.03.25
17:33 Uhr
1,070 Euro
+0,090
+9,18 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MIRA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
MIRA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,9601,00028.03.

Aktuelle News zur MIRA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrMIRA PHARMACEUTICALS, INC. - 10-K, Annual Report1
MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln
MoMIRA Pharmaceuticals signs LOI to acquire SKNY Pharmaceuticals3
MoMIRA Pharmaceuticals to acquire SKNY for obesity, smoking therapy2
MoMIRA Pharmaceuticals erwirbt SKNY für Adipositas- und Raucherentwöhnungstherapie1
MoMIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development179Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking. MIAMI, FL / ACCESS Newswire /...
► Artikel lesen
MoMIRA PHARMACEUTICALS, INC. - 8-K, Current Report2
MoEXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug3
13.03.MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain145MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...
► Artikel lesen
13.03.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report2
13.03.EXCLUSIVE: MIRA Pharmaceuticals Expands Pipeline, Enhances Value Proposition With Development Of Topical Formulation For Lead Pain Treatment Candidate4
04.03.MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain171MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...
► Artikel lesen
04.03.EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain4
04.03.MIRA PHARMACEUTICALS, INC. - 8-K, Current Report-
19.12.24Mira Pharmaceuticals, Inc.: MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development214MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...
► Artikel lesen
19.12.24EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment5
19.12.24MIRA PHARMACEUTICALS, INC. - 8-K, Current Report3
10.12.24Mira Pharmaceuticals, Inc.: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End297Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain MIAMI, FL / ACCESSWIRE / December 10, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage...
► Artikel lesen
10.12.24EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain4
10.12.24MIRA PHARMACEUTICALS, INC. - 8-K, Current Report1
20.11.24MIRA Pharmaceuticals: MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site240Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment MIAMI, FL / ACCESSWIRE / November 20, 2024 /...
► Artikel lesen
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2